AIM ImmunoTech stock analysis
AIM ImmunoTech (HXB) Stock Price & Analysis
HXB Stock Chart & Stats
- Day’s Range
- EUR 6.09 - EUR 6.09
- 52-Week Range
- EUR 6.09 - EUR 6.09
- Previous Close
- EUR 6.09
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 5.35M
- Enterprise Value
- -EUR 1.18M
- Total Cash (Recent Filing)
- EUR 9.96M
- Total Debt (Recent Filing)
- EUR 3.92M
- Price to Earnings (P/E)
- ―
- Beta
- 1.16
- Next Earnings
- Aug 17, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Modest Current Leverage
Modest current debt reduces interest and repayment pressure compared with a heavily leveraged balance sheet. This gives AIM somewhat greater flexibility to direct limited resources toward clinical development, although the benefit is tempered by the company’s ongoing losses and financing needs.
Debt Extinguishment
Fully extinguishing the promissory note removes a defined liability and can simplify the capital structure over the medium term. Lower obligations may reduce near-term balance-sheet pressure, though the transaction achieved that improvement through issuance of additional common shares.
Ampligen Manufacturing Readiness
Expanded manufacturing arrangements support the operational infrastructure needed to supply future Ampligen clinical studies. If development advances, improved trial readiness could help AIM execute programs more consistently and pursue regulatory pathways, although the product remains investigational.
Bears Say
Minimal Revenue And Deep Losses
AIM has not yet demonstrated commercial scale: revenue remains extremely small while gross profit and operating profitability are deeply negative. This limits internally generated funding for research and leaves future progress dependent on successful development, partnerships, or external capital.
Persistent Cash Burn
Sustained negative operating and free cash flow means AIM is consuming cash to fund operations rather than generating resources internally. Continued burn can constrain clinical investment and increase the need for financing, especially if development spending remains elevated over the coming quarters.
Equity Financing And Dilution Risk
Using common shares to retire debt reduces liabilities but increases the share count and can dilute existing holders. Repeated reliance on equity-based financing may remain a structural risk while losses and cash outflows persist, potentially limiting per-share participation in any future success.
HXB FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
What is AIM ImmunoTech’s market cap?
When is AIM ImmunoTech’s upcoming earnings report date?
How were AIM ImmunoTech’s earnings last quarter?
Is AIM ImmunoTech overvalued?
Does AIM ImmunoTech pay dividends?
What is AIM ImmunoTech’s EPS estimate?
How many shares outstanding does AIM ImmunoTech have?
What happened to AIM ImmunoTech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AIM ImmunoTech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas K. Equels
- Employees
- 19
- Website
- aimimmuno.com
- Address
- 2117 SW Highway 484, Ocala, FL, 34473, US
AIM ImmunoTech (HXB) Earnings & Revenues
HXB Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.
View all DE:HXB earnings summariesHXB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 7 | 5 |
| Technical Analysis | 0 | 1 | 1 |
| Moving Averages | 2 | 6 | 4 |
